Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation
Viruses · 2026
DOI: 10.3390/v18090933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2026. Verfasst von Khadija Khalid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Receptors, CCR5, Hematopoietic Stem Cell Transplantation, HIV Infections, Janus Kinases. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VAMC-CT, Fred Kunnes Fund.
Abstract (Originalsprache)
C-C chemokine receptor type 5 (CCR5) is the primary co-receptor mediating the entry of R5-tropic human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells and macrophages, making it one of the most promising therapeutic targets in HIV cure research. The naturally occurring CCR5Δ32 mutation which abolishes surface CCR5 expression in homozygous individuals has provided strong clinical evidence for CCR5-directed strategies after multiple cases of sustained HIV remission following allogeneic hematopoietic stem cell transplantation (HSCT) from CCR5Δ32 donors. This review summarizes the current understanding of the evolutionary origin and global distribution of the CCR5Δ32 allele, as well as the clinical evidence from landmark transplantation cases. We also discuss recent findings demonstrating that durable HIV remission may be achieved following transplantation from heterozygous CCR5 wild-type/Δ32 donors, suggesting that factors such as donor chimerism, conditioning regimens and graft-versus-reservoir effects contribute substantially to reservoir clearance alongside CCR5 disruption. In addition, we examine emerging evidence that pharmacological inhibition of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway can reversibly suppress CCR5 expression, reduce HIV replication, limit reservoir establishment, and attenuate immune activation. Collectively, these advances highlight the evolving landscape of CCR5-targeted therapies and support the development of safer and more broadly applicable approaches toward durable HIV remission and, ultimately, an HIV cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, USA.
ORCID-Profile: Uzair Iqbal, Mohamed Shaltout
Förderung
- VAMC-CT
- Fred Kunnes Fund
Zitieren
APA
Khalid, K., Iqbal, U., Shaltout, M., Yukselten, Y., Ahmad, F., Khalid, A. R., & Sutton, R. E. (2026). Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation. Viruses. https://doi.org/10.3390/v18090933
Vancouver
Khalid K, Iqbal U, Shaltout M, Yukselten Y, Ahmad F, Khalid AR, et al. Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation. Viruses. 2026. doi:10.3390/v18090933
BibTeX
@article{Khalid2026,
author = {Khalid, Khadija and Iqbal, Uzair and Shaltout, Mohamed and Yukselten, Yunus and Ahmad, Farooq and Khalid, Abdur Rehman and Sutton, Richard E},
title = {Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18090933}
}
EUVIMED